Navigation Links
Research identifies first method for testing, assessing drug treatments for Chagas' disease
Date:4/20/2008

Athens, Ga. Chagas disease is a tropical parasitic sickness that currently affects more than 16 million people, with a staggering 100 million at risk, largely in the tropical areas of South and Central America. And yet the main drug used to treat the disease is highly toxic and causes serious side effects.

Now, new research just published by scientists at the University of Georgia has identified for the first time a sensitive method for testing and assessing the efficacy of treatments for Chagas disease. The study could lead to new treatments for long-term sufferers of a disease that can be fatal.

It is the first time weve been able to identify a set of measurements to determine whether or not a drug for Chagas actually works, said Rick Tarleton, distinguished research professor of cellular biology and a faculty member at UGAs Center for Tropical and Emerging Global Diseases.

The research was published today in the online edition of the journal Nature Medicine. Co-authors, also from the University of Georgia, are postdoctoral associate Juan Bustamante and masters degree student Lisa Bixby.

The research presents the first and only evidence that the current drug therapies for Chagas disease can actually completely cure the infection. Still, current treatments have potentially severe side effects and are thought to be effective in less than 50 percent of those treated. More important, the model the team developed can be used for the development of better drugs against Trypanosoma cruzi, the parasite that causes the disease.

We also found that the immunological markers of cure in this system, which we developed in mice, provide a means to monitor drug treatment efficacy in humans, something that has been the biggest impediment to developing new drugs, said Tarleton.

Theres a fourth finding more important to the big picture of immunology, however. This study shows that chronic infections do not by default exh
'/>"/>

Contact: Kim Osborne
kosborne@uga.edu
706-583-0913
University of Georgia
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Newly created cancer stem cells could aid breast cancer research
3. Dominant cholesterol-metabolism ideas challenged by new research
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. U of MN researchers discover noninvasive diagnostic tool for brain diseases
10. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
11. Story ideas from the Journal of Lipid Research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Reportlinker Adds Biotechnology Instrumentation - International Market Trends 2Reportlinker Adds Biotechnology Instrumentation - International Market Trends 3Reportlinker Adds Biotechnology Instrumentation - International Market Trends 4Reportlinker Adds Biotechnology Instrumentation - International Market Trends 5Reportlinker Adds Biotechnology Instrumentation - International Market Trends 6Reportlinker Adds Biotechnology Instrumentation - International Market Trends 7SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project 2Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4